ASX · AVE.AX
Avecho Biotechnology Limited
A$0.01+A$0.00 (+7.69%)
Avecho Biotechnology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.15% below the high.
Loading market information…
OTC · EIGRQ · USD
Stock price, earnings
Quote as of Sep 19, 2024, 03:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Eiger BioPharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Eiger BioPharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical firm dedicated to discovering and advancing treatments for critical health issues, particularly hepatitis delta virus (HDV), among other severe diseases. The company's marketed product, Zokinvy, is prescribed for patients suffering from Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its development pipeline includes several key candidates: Lonafarnib: An orally administered farnesylation inhibitor that has successfully concluded Phase 3 clinical trials for HDV infection. Peginterferon Lambda (lambda): Currently in clinical development for HDV, this compound is also being investigated in Phase II and III investigator studies for mild to moderate COVID-19. Avexitide: This therapy is in Phase II trials for treating congenital hyperinsulinism and post-bariatric hypoglycemia. Based in Palo Alto, California, the company recently announced a significant corporate event: on April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliated entities, submitted a voluntary petition for reorganization under Chapter 11 to the U.S. Bankruptcy Court for the Northern District of Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2022 | Sep 29, 2022 | -$18.48-21.94% vs estimate | $4.02M-5.5% vs estimate |
|---|
| Q1 2022 | Jun 29, 2022 | -$15.25 | $4.09M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.01+A$0.00 (+7.69%)
Avecho Biotechnology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.15% below the high.
$0.82+$0.78 (+2,173.99%)
Titan Medical Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.25% below the high.
$2.11+$0.11 (+5.5%)
Progressive Care, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.11% below the high.
$0.17-$0.03 (-13.04%)
Ceapro Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.39% below the high.
$0.27+$0.01 (+2.88%)
MGC Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 94.75% below the high.
$0.03+$0.01 (+24.39%)
Living Cell Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 61.75% below the high.
CA$0.11+CA$0.01 (+10.0%)
Rapid Dose Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 42.11% below the high.
A$0.05A$0.00 (0.0%)
Noxopharm Limited’s quoted price sits in the lower half of its reported 52-week range, 55.45% below the high.
